menu
    • menu

    Company profile for Gentec Pharmaceutical Group

    Gentec-PSE
    News
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets

    18 Dec 2025

    // PRESS RELEASE

    Gentec Gets AENOR GDP Certification for Meds & APIs

    28 Aug 2025

    // PRESS RELEASE

    GENTEC starts a new era with GENTHEALTH

    31 May 2023

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Gentec VB RM

    Contact Supplier

    Website

    Asia Pharma Expo

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.pharmacompass.com/video-pharmareel/gentec-pharmaceutical-group/your-global-ally-in-the-pharmaceutical-industry

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Related CompaniesRelated Companies

    About

    Gentec Pharmaceutical Group, with over 40 years of experience, is a leader in raw materials and ingredients for food, dietary, and nutrition sectors. It manufactures and commercializes more than 200 APIs and a wide range of finished products. Through Duke Chem and Pharmanoid plants, Gentec offers API, intermediate, and HPAPI development and manufacturing, plus regulatory and legal services including licenses and market assessment. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gentec Pharmaceutical GroupSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Plaça d'Europa 9-11, 3B 08908 L'Hospitalet de Llobregat, Barcelona
    Telephone
    Telephone
    +34 934267750
    Client Email
    Email
    sales@gentec.es
    Client Website
    Website
    https://www.gentec.es/
    Linkedin
    Linkedin
    https://es.linkedin.com/company/gentec-sa
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    VLOG #PharmaReel

    read-more

    ReelPharmaYour Global Ally in the Pharmaceutical IndustryYour Global Ally in the Pharmaceutical Industry

    Your Global Ally in the Pharmaceutical Industry
    Your Global Ally in the Pharmaceutical Industry

    reelYour Global Ally in the Pharmaceutical Industry

    This PharmaReel highlights Gentec Pharmaceutical's expertise in generic APIs, HPAPIs, and prostaglandins with more than 40 years of experience. Operating from EU-GMP-certified facilities, the company exports to over 70 countries worldwide.

    Impressions: 1975

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/gentec-pharmaceutical-group-party-content-20136.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/gentec-pharmaceutical-group-party-content-24802.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/gentec-pharmaceutical-group-party-content-80424.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    COMPANY BIO #AboutSupplier

    read-more
    read-more
    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.
    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.
    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.Q1. What is a highly potent API (HPAPI)?A highly potent API (HPAPI) is defined as an active pharmaceu...
    #LearnMore
    April, 2022
    Share Share
    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.

    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.

    Overview of highly potent or high potency API (HPAPI) & more on Gentec's contract manufacturing services for high potency drugs on PharmaCompass.Q1. What is a highly potent API (HPAPI)?A highly potent API (HPAPI) is defined as an active pharmaceutical ingredient (API) with biological activity at approximately 150 µg/kg of body weight or below in humans (therapeutic daily dose at or below 10 mg). High potent active pharmaceutical ingredients (HPAPI) are effective at much smaller dosage levels when compared to traditional APIs. These high potency drugs usually have the ability to bind selectively at low doses to specific receptors or inhibit specific enzymes as part of oncology or hormonal therapies.Highly potent APIs or high-potency APIs (HPAPIs) are synthesized through multiple process steps that require advanced technologies like peptide coupling, mPEG/PEGylation, chiral resolution, biocatalysis, continuous processing and cryogenic reactions.Because a growing number of pharmaceutical products contain highly potent active pharmaceutical ingredients (HPAPI), demand for the production of HPAPIs has increased. Driven by oncology research and more targeted therapies, highly potent APIs are being increasingly used in the drug development pipeline. The high potency drugs mark a significant change in the way innovators are using small molecules to deliver new patient therapies.Driven by its use in oncology, the global market for highly potent active pharmaceutical ingredients (HPAPI) is registering a high growth. An increase in the clinical pipeline of highly potent API (HPAPI), ADCs and biologics, have changed the demands of contract manufacturing service providers such as CMOs or CDMOs for the production & development services for HPAPIs (highly potent APIs).High-potency active pharmaceutical ingredients (HPAPIs) are a niche but fast growing area for pharmaceutical manufacturers like contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These highly potent APIs, also known as  high-potency APIs (HPAPIs), require multi-step processes or semi-synthesis, necessitating specialized considerations in facility design, equipment, operation and process safety to achieve the requisite level of containment for the high potency APIs (HPAPIs).Only a few CMOs have the HPAPI capabilities to offer both production & development services for HPAPIs (highly potent APIs) and to scale-up small-scale development lab quantities to large-scale commercial volumes. The main advantage of outsourcing HPAPI contract manufacturing services or contract manufacturing of highly potent compounds is that it eliminates the need to invest in costly containment infrastructure that can also be difficult to engineer, install and maintain.Q2. What are some different containment challenges associated with high-potency APIs (HPAPIs)? How are these challenges addressed?Production & development services for HPAPIs (highly potent APIs) present a new set of challenges in terms of safe handling and containment during process development, clinical and large-scale production of highly potent API.The containment challenges associated with high-potency APIs are noted below: The cytotoxic nature of highly potent APIs presents significant handling challenges, and thus requires heavy investments for the implementation of specialized containment facilities.     Employee exposure to highly potent APIs is typically the primary area of concern for manufacturers of HPAPI.     The early HPAPI (highly potent API) development phase sometimes creates a challenge for categorization. At times, sufficient information is not available to allow for a clear assessment of risks.     Additionally, the manufacturing of high-potency active pharmaceutical ingredients (HPAPIs) requires an isolated environment that is usually equipped with isolators and cleanrooms.     It is a challenge to protect the API from contamination or cross-contamination from other HPAPIs made in the facility or the site. This risk can come from both previous and concurrent operations.     Working with highly potent active pharmaceutical ingredients (HPAPIs), which are highly potent and cytotoxic, entails a slew of regulations and requirements. It also poses challenges for pharmaceutical companies (eg. CDMO, CMO) in terms of handling, containment and cost for HPAPI contract manufacturing services.Working with an experienced pharmaceutical outsourcing organization such as a CMO or CDMO for  contract manufacturing of highly potent compounds, can help eliminate challenges like investing in expensive infrastructure and the cost of training staff for the production of an highly potent API and offering HPAPI contract manufacturing services.Containment challenges can be handled through the following ways:Large-scale production of highly potent API necessitates specialized approaches in facility design, equipment selection and manufacturing processes to overcome high potency API (HPAPI) containment challenges, to minimize exposure of operators and to ensure the protection and safety of the workers. For successful HPAPI (highly potent API) development, extensive knowledge and experienced staff are required. Highly potent active pharmaceutical ingredients (HPAPIs) have a specific occupational exposure limit (OEL) that must be kept in mind to ensure safe handling, as there is a selective process in choosing the most appropriate containment strategy.     To avoid contaminating surfaces and to establish a safe working environment for employees, it is essential to put a thorough cleaning program in place.     The entire isolator should be cleanable in a reproducible and quantifiable manner to avoid any chance of cross-contamination. During qualification, swab tests and tracer substances should be used.     It is necessary to carry out a careful assessment of the hazards posed by each and every product, reagent and intermediate involved in the synthesis before manufacturing highly potent API (HPAPI).     Sophisticated facility design elements that are used to address containment challenges for a highly potent active pharmaceutical ingredient (HPAPI) include several tools to ensure safe handling of HPAPIs. In addition, well-designed protection methods include nuanced and detailed processes regarding how workers should use and clean HPAPI manufacturing A­assets.     A manufacturer of HPAPI should consider several areas in order to safely manage highly potent active pharmaceutical ingredients (HPAPIs) processes. For example, proper training should be provided to offer staff a comprehensive High Potency API (HPAPI) handling programme.     Following standard risk management and industrial hygiene methodology, it is critical to first recognize, analyze and control the handling of high potency drugs and then to revisit this process on a regular basis, capturing any changes in the available product data, manufacturing processes, etc.Q3. What are the recent trends in the manufacturing of highly potent drugs?An increasing focus on highly potent active pharmaceutical ingredients (HPAPI) in the pharmaceutical development pipeline has resulted in a growing demand for HPAPI capabilities to safely handle and contain such hazardous ingredients. A high potency API (HPAPI) has the potential to achieve similar efficacy at a lower dose than conventional APIs, which is appealing to drug developers because it reduces patient exposure to medication.High-potency APIs (HPAPIs) are becoming increasingly popular. Around a third of all drugs in the pharmaceutical pipeline are categorized as high potency active pharmaceutical ingredients (HPAPIs). With the market size for High Potency API (HPAPI) expected to grow at a CAGR of 8-10% through 2025, this percentage is likely to increase further.With this changing landscape and the focus being on high-potency APIs (HPAPIs), the challenges in HPAPI and cytotoxic drugs manufacturing have also increased, along with investments, in terms of specialized containment areas and procedures to prevent personnel and environmental exposure. A pharmaceutical CMO or CDMO has the capability to offer HPAPI Contract Manufacturing Services.Isolator design, laboratory design and containment practices are critical for safe HPAPI and cytotoxic drugs manufacturing. The advancement of technology and knowledge has greatly improved worker safety, but this has led to a corresponding increase in the cost of facility design, construction and operation.While a key focus in HPAPI and cytotoxic drugs manufacturing is the adaptation of traditional processing techniques to maximize containment, new technologies such as continuous flow manufacturing (CFM) are particularly promising, where closed systems can be utilized to improve upon traditional containment practices.The shift towards highly potent API (HPAPIs) has led to more effective medicines, with potentially lower dose requirements and fewer side effects. HPAPI manufacturing also presents major handling challenges for innovators and their developers as well as  manufacturers of HPAPI.Companies are now looking for flexible containment solutions to help address their needs. This trend is expected to continue to grow in the coming years. However, if the current development focus on highly potent API (HPAPIs) continues to show more efficacy and fewer side effects than currently marketed products, highly Potent drugs are likely to become one of the most dominant areas in the industry.Continuous flow manufacturing (CFM) is highly attractive for large-scale production of highly potent API. It holds a lot of promise for experienced chemical process development and engineering groups to design safer and more efficient processes in the future.Q4. What pharmaceutical HPAPI manufacturing services does Gentec offer?Gentec is a contract manufacturing organization (CMO) which manufactures APIs (active pharmaceutical ingredients), HPAPIs (high-potency active pharmaceutical ingredients), advanced intermediates and fine chemicals for the pharmaceutical industry. It also provides raw materials to the food industry.Gentec, at its Duke Chem and Pharmanoid facilities, offers the development and manufacture of APIs, intermediates and contract manufacturing of highly potent compounds. Its multipurpose and multi-product facilities are cGMP compliant. A team of over 60 employees, including specialized professionals with extensive experience in the chemical and pharmaceutical sector, make up the workforce.Gentec's Pharmanoid plant develops and manufactures high-potency active pharmaceutical ingredients (HPAPIs), including several prostaglandins for ophthalmic use. The facility is cGMP certified, allowing it to handle high-potency active pharmaceutical ingredients (HPAPIs) while providing a safe environment for the people.Gentec's multifunctional plants have HPAPI capabilities and can carry out complex multi-step industrial processes. Gentec not only offers HPAPI contract manufacturing services, but is also involved in the distribution of APIs.

    Impressions: 1684

    NEWS #PharmaBuzz

    read-more
    read-more
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets
    Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets

    18 Dec 2025

    // PRESS RELEASE

    https://www.inke.es/news/inke-acquires-pharmanoid-a-highly-potent-api-manufacturing-site-specializing-in-ophthalmology/

    PRESS RELEASE
    18 Dec 2025
    Share Share
    Gentec Gets AENOR GDP Certification for Meds & APIs
    Gentec Gets AENOR GDP Certification for Meds & APIs

    28 Aug 2025

    // PRESS RELEASE

    https://www.gentec.es/gentec-obtains-certification-for-good-distribution-practices-for-medicines-and-apis-from-aenor/?lang=en

    PRESS RELEASE
    28 Aug 2025
    Share Share
    GENTEC starts a new era with GENTHEALTH
    GENTEC starts a new era with GENTHEALTH

    31 May 2023

    // PRESS RELEASE

    https://www.gentec.es/gentec-abre-una-nueva-era-con-genhealth/

    PRESS RELEASE
    31 May 2023
    Share Share
    NEW OFFICES -Gentec Pharmaceutical Group
    NEW OFFICES -Gentec Pharmaceutical Group

    23 Feb 2022

    // PRESS RELEASE

    https://www.gentec.es/nuevas-oficinas/

    PRESS RELEASE
    23 Feb 2022
    Share Share
    Strategy for the evaluation of occupational exposure to chemical substances / APIs
    Strategy for the evaluation of occupational exposure to chemical substances / APIs

    09 Sep 2017

    // INTEREM PRESS

    https://www.pharmacompass.com/pdf/news/strategy-for-the-evaluation-of-occupational-exposure-to-chemical-substances-apis-1526029076.pdf

    INTEREM PRESS
    09 Sep 2017
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Sales, Marketing, Registration

    Discover their expertise for : Sales, Marketing, Registration

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Gentec full-view

    TOP RANKED SUPPLIER FOR:

    GMP Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    EDQM

    read-more
    read-more

    01

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/2417...

    EudraGMDP Key : 172472

    Country : Spain

    Issue Date : 2024-09-13

    Post Code :

    NCA Ref : 10120-001

    City : Olerdola

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/2412...

    EudraGMDP Key : 171394

    Country : Spain

    Issue Date : 2024-06-20

    Post Code :

    NCA Ref : 10120-001

    City : Olerdola

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/2332...

    EudraGMDP Key : 166003

    Country : Spain

    Issue Date : 2023-11-07

    Post Code :

    NCA Ref : 10120-001

    City : Olerdola

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GMP Certified

    EU
    arrow
    Asia Pharma Expo
    Exhibiting

    Gentec Pharmaceutical Group

    Type : GMP Certificates

    Number : NCF-II/2319...

    EudraGMDP Key : 170206

    Country : Spain

    Issue Date : 2023-06-22

    Post Code :

    NCA Ref : 11127-002

    City : Barcelona

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GMP Certified

    EU
    arrow
    Asia Pharma Expo
    Exhibiting

    Gentec Pharmaceutical Group

    Type : GMP Certificates

    Number : NCF-II/2205...

    EudraGMDP Key : 153200

    Country : Spain

    Issue Date : 2022-02-04

    Post Code :

    NCA Ref : 11127-002

    City : Avinyonet Del Penedes

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/2121...

    EudraGMDP Key : 134327

    Country : Spain

    Issue Date : 2021-06-06

    Post Code :

    NCA Ref : 10120-001

    City : OLERDOLA

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/2103...

    EudraGMDP Key : 122942

    Country : Spain

    Issue Date : 2021-01-27

    Post Code :

    NCA Ref : 10120-001

    City : OLERDOLA

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF-II/1924...

    EudraGMDP Key : 54863

    Country : Spain

    Issue Date : 2019-05-31

    Post Code :

    NCA Ref : 10120-001

    City : OLERDOLA

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    GMP Certified

    EU
    arrow
    Asia Pharma Expo
    Exhibiting

    Gentec Pharmaceutical Group

    Type : GMP Certificates

    Number : NCF-II/1901...

    EudraGMDP Key : 55920

    Country : Spain

    Issue Date : 2019-01-15

    Post Code :

    NCA Ref : 11127-002

    City : Avinyonet del Penedes

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    GMP Certified

    EU
    arrow
    Cosmoprof
    Not Confirmed

    Duke Chem

    Type : GMP Certificates

    Number : NCF/1738/00...

    EudraGMDP Key : 42401

    Country : Spain

    Issue Date : 2017-06-13

    Post Code :

    NCA Ref : 10120-001

    City : OLERDOLA

    Gentec Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Gentec Pharmaceutical Group and get a quotation

    Gentec Pharmaceutical Group is a supplier offers 9 products (APIs, Excipients or Intermediates).

    Find a price of Brinzolamide bulk with DMF, JDMF offered by Gentec Pharmaceutical Group

    Find a price of Etofenamate bulk with CEP offered by Gentec Pharmaceutical Group

    Find a price of Azithromycin bulk offered by Gentec Pharmaceutical Group

    Find a price of Bepotastine bulk offered by Gentec Pharmaceutical Group

    Find a price of Dorzolamide Hydrochloride bulk offered by Gentec Pharmaceutical Group

    Find a price of Febuxostat bulk offered by Gentec Pharmaceutical Group

    Find a price of Lifitegrast bulk offered by Gentec Pharmaceutical Group

    Find a price of Nitazoxanide bulk offered by Gentec Pharmaceutical Group

    Find a price of Silodosin bulk offered by Gentec Pharmaceutical Group

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search